Pioglitazone is a member of the thiazolidinedione class, it decreases insulin resistance in the periphery and in the liver resulting in increased insulin dependent glucose disposal and decreased hepatic glucose output.[medical citation needed]
Metformin is a member of the biguanide class, improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.[medical citation needed]
Indicationedit
Pioglitazone/metformin is indicated as an adjunct to diet and exercise:[medical citation needed]
To improve glycemic control in patients with type 2 diabetes, or
For patients who are already treated with a separate combination of pioglitazone and metformin,
For patients whose diabetes is not adequately controlled with metformin alone, or
For patients who have initially responded to pioglitazone alone and require additional glycemic control.
Dosage and administrationedit
Use in pregnancy and lactationedit
Pioglitazone/metformin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. There are no adequate and well-controlled studies in pregnant women with combination of pioglitazone and metformin or its individual components. It is not known whether pioglitazone and/or metformin are secreted in human milk. Because many drugs are excreted in human milk, pioglitazone/metformin should not be administered to a breastfeeding woman.[medical citation needed]
Precautionsedit
Pioglitazone/metformin should not be used in people with type 1 diabetes or for the treatment of diabetic ketoacidosis and should be used with caution in people with edema. Serum ALT levels should be evaluated prior to the initiation of therapy with combination of pioglitazone and metformin and periodically thereafter per the clinical judgment of the health care professional.[medical citation needed]
Side-effectsedit
The most common side-effects are upper respiratory tract infection, diarrhea, combined edema/peripheral edema and headache, respectively. Most clinical adverse events were similar between groups treated with pioglitazone in combination with metformin and those treated with pioglitazone monotherapy.[medical citation needed]
Contraindicationsedit
Pioglitazone/metformin is contraindicated in people with known hypersensitivity to any components of this combination. These combination also contraindicated in renal disease which may also result from conditions, e.g., acute myocardial infarction, sepsis, acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.[medical citation needed]
Drug interactionedit
Pioglitazone/metformin may interact with furosemide, nifedipine, cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) and certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control (e.g., thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid).[medical citation needed]
Referencesedit
^"Competact 15 mg/850 mg film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 12 August 2020.
^ abc"Actoplus Met XR- pioglitazone and metformin hydrochloride tablet, film coated, extended release". DailyMed. 4 October 2019. Retrieved 12 August 2020.
pioglitazone, metformin, this, article, needs, additional, citations, verification, please, help, improve, this, article, adding, citations, reliable, sources, unsourced, material, challenged, removed, find, sources, news, newspapers, books, scholar, jstor, se. This article needs additional citations for verification Please help improve this article by adding citations to reliable sources Unsourced material may be challenged and removed Find sources Pioglitazone metformin news newspapers books scholar JSTOR September 2012 Learn how and when to remove this template message Pioglitazone metformin sold under the brand name Actoplus Met among others is a fixed dose combination anti diabetic medication used to improve glycemic control in adults with type 2 diabetes 3 2 It contains pioglitazone a thiazolidinedione and metformin a biguanide 2 Pioglitazone metforminCombination ofPioglitazoneThiazolidinedioneMetforminBiguanideClinical dataTrade namesActoplus Met Piomet Politor othersAHFS Drugs comProfessional Drug FactsLicense dataUS DailyMed Pioglitazone and metforminRoutes ofadministrationBy mouthATC codeA10BD05 WHO Legal statusLegal statusUK POM Prescription only 1 US only 2 EU Rx only 3 In general Prescription only IdentifiersCAS Number737811 27 7KEGGD09744 Contents 1 Mechanisms 2 Indication 3 Dosage and administration 3 1 Use in pregnancy and lactation 3 2 Precautions 4 Side effects 5 Contraindications 6 Drug interaction 7 ReferencesMechanisms editPioglitazone is a member of the thiazolidinedione class it decreases insulin resistance in the periphery and in the liver resulting in increased insulin dependent glucose disposal and decreased hepatic glucose output medical citation needed Metformin is a member of the biguanide class improves glucose tolerance in patients with type 2 diabetes lowering both basal and postprandial plasma glucose Metformin decreases hepatic glucose production decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization medical citation needed Indication editPioglitazone metformin is indicated as an adjunct to diet and exercise medical citation needed To improve glycemic control in patients with type 2 diabetes or For patients who are already treated with a separate combination of pioglitazone and metformin For patients whose diabetes is not adequately controlled with metformin alone or For patients who have initially responded to pioglitazone alone and require additional glycemic control Dosage and administration editUse in pregnancy and lactation edit Pioglitazone metformin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus There are no adequate and well controlled studies in pregnant women with combination of pioglitazone and metformin or its individual components It is not known whether pioglitazone and or metformin are secreted in human milk Because many drugs are excreted in human milk pioglitazone metformin should not be administered to a breastfeeding woman medical citation needed Precautions edit Pioglitazone metformin should not be used in people with type 1 diabetes or for the treatment of diabetic ketoacidosis and should be used with caution in people with edema Serum ALT levels should be evaluated prior to the initiation of therapy with combination of pioglitazone and metformin and periodically thereafter per the clinical judgment of the health care professional medical citation needed Side effects editThe most common side effects are upper respiratory tract infection diarrhea combined edema peripheral edema and headache respectively Most clinical adverse events were similar between groups treated with pioglitazone in combination with metformin and those treated with pioglitazone monotherapy medical citation needed Contraindications editPioglitazone metformin is contraindicated in people with known hypersensitivity to any components of this combination These combination also contraindicated in renal disease which may also result from conditions e g acute myocardial infarction sepsis acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma medical citation needed Drug interaction editPioglitazone metformin may interact with furosemide nifedipine cationic drugs e g amiloride digoxin morphine procainamide quinidine quinine ranitidine triamterene trimethoprim and vancomycin and certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control e g thiazides and other diuretics corticosteroids phenothiazines thyroid products estrogens oral contraceptives phenytoin nicotinic acid sympathomimetics calcium channel blocking drugs and isoniazid medical citation needed References edit Competact 15 mg 850 mg film coated Tablets Summary of Product Characteristics SmPC emc Retrieved 12 August 2020 a b c Actoplus Met XR pioglitazone and metformin hydrochloride tablet film coated extended release DailyMed 4 October 2019 Retrieved 12 August 2020 a b Competact EPAR European Medicines Agency EMA Retrieved 11 August 2020 Politor monograph PDF ACI Limited Retrieved 28 September 2012 Portal nbsp Medicine Retrieved from https en wikipedia org w index php title Pioglitazone metformin amp oldid 1214316961, wikipedia, wiki, book, books, library,
